GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt,Andrew D Oxman,Gunn Elisabeth Vist,Regina Kunz,Yngve Falck-Ytter,Pablo Alonso-Coello,Holger J. Schünemann +6 more
Reads0
Chats0
TLDR
The advantages of the GRADE system are explored, which is increasingly being adopted by organisations worldwide and which is often praised for its high level of consistency.Abstract:
Guidelines are inconsistent in how they rate the quality of evidence and the strength of recommendations. This article explores the advantages of the GRADE system, which is increasingly being adopted by organisations worldwideread more
Citations
More filters
Chapter 8: Assessing risk of bias in included studies
TL;DR: The Cochrane Handbook for Systematic Reviews of Interventions (ISBN 978-0470057964) is published by John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England.
Journal ArticleDOI
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
Andrew Rhodes,Laura Evans,Waleed Alhazzani,Mitchell M. Levy,Massimo Antonelli,Ricard Ferrer,Anand Kumar,Jonathan E. Sevransky,Charles L. Sprung,Mark E. Nunnally,Bram Rochwerg,Gordon D. Rubenfeld,Derek C. Angus,Djillali Annane,Richard Beale,Geoffrey J. Bellinghan,Gordon R. Bernard,Jean Daniel Chiche,Craig M. Coopersmith,Daniel De Backer,Craig French,Seitaro Fujishima,Herwig Gerlach,Jorge Hidalgo,Steven M. Hollenberg,Alan E. Jones,Dilip R. Karnad,Ruth M. Kleinpell,Younsuck Koh,Thiago Lisboa,Flávia Ribeiro Machado,John J. Marini,John C. Marshall,John E. Mazuski,Lauralyn McIntyre,Anthony S. McLean,Sangeeta Mehta,Rui Moreno,John Myburgh,Paolo Navalesi,Osamu Nishida,Tiffany M. Osborn,Anders Perner,Colleen M. Plunkett,Marco Ranieri,Christa A. Schorr,Maureen A. Seckel,Christopher W. Seymour,Lisa Shieh,Khalid A. Shukri,Steven Q. Simpson,Mervyn Singer,B. Taylor Thompson,Sean R. Townsend,Thomas Van der Poll,Jean Louis Vincent,W. Joost Wiersinga,Janice L. Zimmerman,R. Phillip Dellinger +58 more
TL;DR: Although a significant number of aspects of care have relatively weak support, evidence-based recommendations regarding the acute management of sepsis and septic shock are the foundation of improved outcomes for these critically ill patients with high mortality.
Journal ArticleDOI
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
TL;DR: This guideline is intended to improve communication about benefits and risks of opioids for chronic pain, improve safety and effectiveness of pain treatment, and reduce risks associated with long-term opioid therapy.
Journal ArticleDOI
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis,Elisabeth Brambilla,Masayuki Noguchi,Andrew G. Nicholson,Kim R. Geisinger,Yasushi Yatabe,David G. Beer,Charles A. Powell,Gregory J. Riely,Paul Van Schil,Kavita Garg,John H. M. Austin,Hisao Asamura,Valerie W. Rusch,Fred R. Hirsch,Giorgio V. Scagliotti,Tetsuya Mitsudomi,Rudolf M. Huber,Yuichi Ishikawa,James R. Jett,Montserrat Sanchez-Cespedes,Jean-Paul Sculier,Takashi Takahashi,Masahiro Tsuboi,Johan Vansteenkiste,Ignacio I. Wistuba,Pan-Chyr Yang,Denise R. Aberle,Christian Brambilla,Douglas B. Flieder,Wilbur A. Franklin,Adi F. Gazdar,Michael K. Gould,Philip S. Hasleton,Douglas W. Henderson,Bruce E. Johnson,David A Johnson,Keith M. Kerr,Keiko Kuriyama,Jin Soo Lee,Vincent A. Miller,Iver Petersen,Victor L. Roggli,Rafael Rosell,Nagahiro Saijo,Erik Thunnissen,M. Tsao,David Yankelewitz +47 more
TL;DR: This new adenocarcinoma classification is needed to provide uniform terminology and diagnostic criteria, especially for bronchioloalveolar carcinoma (BAC), the overall approach to small nonresection cancer specimens, and for multidisciplinary strategic management of tissue for molecular and immunohistochemical studies.
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (Chinese edition)
David Moher,Alessandro Liberati,Alessandro Liberati,Jennifer Tetzlaff,Douglas G. Altman,Gerd Antes,David C. Atkins,Virginia Barbour,N Barrowman,Jesse A. Berlin,J Clark,Mike Clarke,Mike Clarke,Deborah J. Cook,Roberto D'Amico,Roberto D'Amico,Jonathan J Deeks,Philip J. Devereaux,Kay Dickersin,M Egger,E Ernst,P C Gøtzsche,Jeremy M. Grimshaw,G Guyatt,Julian P T Higgins,Ioannidis Jpa.,Jos Kleijnen,Tom Lang,N Magrini,D McNamee,Lorenzo Moja,C Mulrow,M Napoli,A Oxman,B Pham,Drummond Rennie,Margaret Sampson,K F Schulz,P G Shekelle,David Tovey,Peter Tugwell +40 more
TL;DR: Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review registration number 2.
References
More filters
Journal ArticleDOI
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen C. Johnson,Jane Morley Kotchen,Judith K. Ockene +11 more
TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Journal ArticleDOI
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen B. Hulley,Deborah Grady,Trudy L. Bush,Curt D Furberg,David M. Herrington,Betty Riggs,Eric Vittinghoff +6 more
TL;DR: Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.
Journal ArticleDOI
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Echt Ds,Philip R. Liebson,Mitchell Lb,Robert W. Peters,Obias-Manno D,Barker Ah,Arensberg D,Baker A,Lawrence S. Friedman,Greene Hl +9 more
TL;DR: There was an excess of deathsDue to arrhythmia and deaths due to shock after acute recurrent myocardial infarction in patients treated with encainide or flecainide.
Journal ArticleDOI
A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction.
TL;DR: Finding and analyzing all therapeutic trials in a given field has become such a difficult and specialized task that the clinical experts called on to summarize the evidence in a timely fashion need access to better databases and new statistical techniques to assist them.
Journal ArticleDOI
Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group.
David Atkins,Martin P Eccles,Signe Flottorp,Gordon H. Guyatt,David Henry,Suzanne Hill,Alessandro Liberati,Dianne L. O'Connell,Andrew D Oxman,Bob Phillips,Holger J. Schünemann,Holger J. Schünemann,Tessa Tan-Torres Edejer,Gunn Elisabeth Vist,John W Williams +14 more
TL;DR: The objective was to critically appraise six prominent systems for grading levels of evidence and the strength of recommendations as a basis for agreeing on characteristics of a common, sensible approach.